Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096716 | 1.00 | MEN1 (0.31) | MEN1HTTKMT2AL3MBTL1CA1 | |
| SCHEMBL20974178 | 0.87 | MEN1 (0.34) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL2788268 | 0.82 | ACACB (0.33) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL18340854 | 0.82 | ACACB (0.33) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL20480362 | 0.80 | GABRR1 (0.40) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL20974323 | 0.80 | GABRR1 (0.40) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL1023140 | 0.80 | GABRR1 (0.40) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL9129576 | 0.79 | MEN1 (0.34) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL16699764 | 0.78 | THRB (0.34) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL13731404 | 0.77 | MEN1 (0.33) | MEN1HTTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106317072-B | Heterocyclic compounds for the treatment of mycobacterial infections and uses thereof | 盟科医药技术(上海)有限公司 | 2020-03-17 | — | — | CN | disclosed |
| US-20090221655-A1 | ANTIBACTERIAL AGENTS | PITZER, INC. (US) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221655-A1 | ANTIBACTERIAL AGENTS | OXSR1, CBR3, AOC3 | MEN1 3546/4885HTT 2255/4885KMT2A 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.